| Arrowhead Pharmaceuticals, Inc. | |
| Native Name Lang: | English |
| Type: | Public |
| Hq Location: | Pasadena, California, U.S. |
| Industry: | Biotechnology |
| Key People: | Christopher Anzalone, Ph.D., president and chief executive officerJavier San Martin, M.D., Chief Medical OfficerKen Myszkowski, MBA, CPA, chief financial officerJames Hamilton, M.D., MBA, Chief Discovery and Translational Medicine |
| Revenue: | $243.2 million(2022)[1] |
| Num Employees: | 376 |
Arrowhead Pharmaceuticals is a publicly traded biopharmaceutical company based in Pasadena, California. Arrowhead’s products in development act through RNA interference (RNAi) mechanisms of action.[2] [3] The company focuses on treatments for hepatitis B, liver disease associated with alpha 1-antitrypsin deficiency and cardiovascular disease. The company has sixteen products in its pipeline, in various stages of development.
| Product | Indication | Notes | ||
|---|---|---|---|---|
| ARO-HBV | In clinic, phase 2 | Licensed with Janssen, Phase 2 | ||
| ARO-AAT | In clinic, phase 3 | Orphan Drug designation, partnered with Takeda | ||
| ARO-APOC3 | Phase 2, 3 | Orphan Drug designation, Fast Track Designation, Phase 3 for FCS, Phase 2 for expanded populations | ||
| ARO-HIF2 | Renal cell carcinoma | Preclinical | Second generation being worked on presumably | |
| ARO-ENaC | Cystic fibrosis | Preclinical | Second generation being worked on in preclinic | |
| ARO-ANG3 | In clinic, Phase 2 | Orphan Drug designation | ||
| Olpasiran/ AMG 890 | Cardiovascular disease | In clinic, phase 3 | Partnered with Amgen | |
| ARO-PNPLA3 | NASH | In clinic, Phase 1 | License returned to ARWR | |
| ARO-HSD | NASH | In clinic, Phase 1 | Licensed to GSK | |
| ARO-C3 | Complement Mediated Disease | In clinic, Phase 1 | ||
| ARO-MUC5AC | Muco-obstructive | In clinic, Phase 1 | ||
| ARO-RAGE | Inflammatory | In clinic, Phase 1 | ||
| ARO-MMP7 | Idiopathic Pulmonary Fibrosis | In clinic, Phase 1 | ||
| ARO-COV | Covid-19 | Preclinical | ||
| ARO-DUX4 | FSHD | Preclinical | ||
| HZN-457 | Gout | In clinic, Phase 1 | Partnered with Horizon |
In 2015, the company substantially expanded its intellectual property holdings through complete acquisition of the full RNAi research and development portfolio, and assets from Novartis.[4] [5]
In April 2016, it was announced that the former company name, Arrowhead Research Corporation, will be changed to Arrowhead Pharmaceuticals, Inc.[6]
In September 2016, Arrowhead entered into two collaboration and licensing agreements with Amgen. Under the deals, Amgen received a worldwide exclusive license to Arrowhead’s ARO-LPA RNAi program and an option to a worldwide exclusive license for ARO-AMG1, both for cardiovascular disease.[7]
On Oct. 31, 2018, Arrowhead Pharmaceuticals Inc. closed on a $3.7 billion license and collaboration agreement with Janssen to develop and commercialize ARO-HBV. As part of the deal, Arrowhead entered into a research collaboration and option agreement with Janssen to potentially collaborate for up to three more RNA interference (RNAi) therapeutics against new targets to be selected by Janssen.[8]